Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 110

Similar articles for PubMed (Select 16553091)

1.

CA 19-9: not a magic marker for pancreatic cancer.

Daram SR.

South Med J. 2006 Mar;99(3):205. No abstract available.

PMID:
16553091
2.

CA 19-9 in the presence of obstructive jaundice due to Mirizzi syndrome.

Gibor U, Perry ZH, Netz U, Glazer Y, Laufer L, Kirshtein B.

Isr Med Assoc J. 2015 Jan;17(1):60-1. No abstract available.

3.

Establishment of an orthotopic model of pancreatic cancer to evaluate the antitumor effects of irinotecan through the biomarker carbohydrate antigen 19-9 in mice.

Li L, Yue GG, Fung KP, Leung PC, Lau CB, Leung PS.

Pancreas. 2014 Oct;43(7):1126-8. doi: 10.1097/MPA.0000000000000183. No abstract available.

PMID:
25207664
4.

A rare finding of direct esophageal metastasis from a pancreatic primary tumor.

Murakami T, Elquza E, Ozden N, Pugh J.

Pancreas. 2014 Oct;43(7):1123-5. doi: 10.1097/MPA.0000000000000192. No abstract available.

PMID:
25207662
5.

Pancreatic cancer: new hopes for early detection and a future screening tool?

El-Jurdi NH, Saif MW.

JOP. 2014 Jul 28;15(4):358-9. doi: 10.6092/1590-8577/2696.

6.

Proteins in blood reveal pancreatic tumors.

Schmidt C.

J Natl Cancer Inst. 2014 Jul 8;106(7). pii: dju225. doi: 10.1093/jnci/dju225. Print 2014 Jul. No abstract available.

PMID:
25006198
7.

Extremely high level of CA 19-9 in a patient with metastatic pancreatic cancer: second highest level of CA 19-9 in literature.

Cemal Kizilarslanoglu M, Civelek R, Kemal Kilic M, Kerem M, Gunaydin Y, Ulger S.

J BUON. 2014 Apr-Jun;19(2):583-4. No abstract available.

PMID:
24965432
8.

Response to: Platelet indices in differential diagnosis of pancreatic neuroendocrine tumors from pancreatic adenocarcinomas.

Karaman K, Kurt M, Aksoy E.

Eur J Intern Med. 2014 Jul;25(6):e83. doi: 10.1016/j.ejim.2014.05.004. Epub 2014 May 27. No abstract available.

PMID:
24873725
9.

Biomarkers in blood could help to detect pancreatic cancer.

Tanday S.

Lancet Oncol. 2014 Mar;15(3):e108. No abstract available.

PMID:
24809088
10.

Platelet indices in differential diagnosis of pancreatic neuroendocrine tumors from pancreatic adenocarcinomas.

Varol E.

Eur J Intern Med. 2014 Jul;25(6):e82. doi: 10.1016/j.ejim.2014.02.004. Epub 2014 Feb 26. No abstract available.

PMID:
24582330
11.

Pancreatic cancer: practical strategies for early diagnosis and management.

Tannery KM, Rizzolo D.

JAAPA. 2013 Oct;26(10):27-32. doi: 10.1097/01.JAA.0000435004.09599.30.

PMID:
24201918
12.

Biomarkers for pancreatic cancer: promising new markers and options beyond CA 19-9.

Ballehaninna UK, Chamberlain RS.

Tumour Biol. 2013 Dec;34(6):3279-92. doi: 10.1007/s13277-013-1033-3. Epub 2013 Aug 17. Review.

PMID:
23949878
13.

CA 19-9 and pancreatic cancer.

Wu E, Zhou S, Bhat K, Ma Q.

Clin Adv Hematol Oncol. 2013 Jan;11(1):53-5. No abstract available.

14.

Re: CA 19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and preoperative therapy.

Bold RJ.

Ann Surg Oncol. 2013 Jul;20(7):2108-10. doi: 10.1245/s10434-012-2820-6. No abstract available.

PMID:
23563959
15.

CA 19-9 concentration in peripheral and portal blood of patients operated on for pancreatic tumor.

Szwedziak K, Strzelczyk J.

Pol Przegl Chir. 2013 Jan;85(1):20-8. doi: 10.2478/pjs-2013-0004.

PMID:
23509198
16.

CA 19-9 tumor marker: is it reliable? A case report in a patient with pancreatic cancer.

Wu Z, Kuntz AI, Wadleigh RG.

Clin Adv Hematol Oncol. 2013 Jan;11(1):50-2. No abstract available.

PMID:
23416865
17.

Circulating molecular markers in pancreatic cancer: ready for clinical use?

Gall TM, Frampton AE, Krell J, Castellano L, Jiao LR.

Future Oncol. 2013 Feb;9(2):141-4. doi: 10.2217/fon.12.187. No abstract available.

PMID:
23414463
18.

The clinical utility of CA 19-9 in pancreatic adenocarcinoma: diagnostic and prognostic updates.

Poruk KE, Gay DZ, Brown K, Mulvihill JD, Boucher KM, Scaife CL, Firpo MA, Mulvihill SJ.

Curr Mol Med. 2013 Mar;13(3):340-51. Review.

19.

CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy.

Hartwig W, Strobel O, Hinz U, Fritz S, Hackert T, Roth C, B├╝chler MW, Werner J.

Ann Surg Oncol. 2013 Jul;20(7):2188-96. doi: 10.1245/s10434-012-2809-1. Epub 2012 Dec 18.

PMID:
23247983
20.

Biomarkers in pancreatic cancer: diagnostic, prognostic, and predictive.

Fong ZV, Winter JM.

Cancer J. 2012 Nov-Dec;18(6):530-8. doi: 10.1097/PPO.0b013e31827654ea. Review.

PMID:
23187839
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk